Many patients with non-small cell lung cancer (NSCLC) have no identifiable mutations, and therefore their disease cannot be managed with targeted treatments. These patients often experience disease progression despite chemotherapy. However, a study led by investigators at Weill Cornell Medical Medicine used a new approach to examine crosstalk between cancer cells and cells in the microenvironment in NSCLC. Instead of looking at the tumor as a whole, the researchers used deep sequencing of RNA to analyze individual cell populations isolated from NSCLC specimens, an approach that could someday lead to new treatments for patients with NSCLC.
February 21, 2017